Strategic collaborations Growing partnership activity with biotechs and foundations (e.g., Evolyra Therapeutics, Drake Rayden Foundation, Jaguar Gene Therapy) indicates a receptive market for CDMO services across gene therapy development stages, suggesting targeted outreach to similar entities focusing on LGMD, NKH, PMS and ASD-related programs.

Expanded manufacturing capacity A 180,000-square-foot facility capable of clinical through commercial GMP production and up to 2,000 L scale signals the ability to handle late-stage and commercial programs, presenting opportunities to win PPQ, process validation, and scale-up work for X-linked and monogenic disease therapies.

Viral vector leadership Longstanding viral vector experience and recent launches of a lentiviral vector platform position Andelyn as a preferred partner for clients needing scalable vector development and manufacturing, enabling cross-sell of vector process development, analytical development, and GMP manufacturing services.

Revenue focus With reported revenue in the lower-to-mid hundreds of millions and strategic funding, Andelyn appears financially positioned to invest in expanded capabilities or co-development agreements, making it a strong candidate for multi-year CDMO engagements and risk-sharing deals.

Portfolio momentum Active press coverage of multi-program partnerships across gene therapy targets, including LGMD, SHANK3 haploinsufficiency, and PPQ collaborations, suggests a growing and diversified pipeline ideal for tiered service packages, from early development support to late-stage manufacturing.